176 related articles for article (PubMed ID: 37955186)
1. A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults.
Pezzolo E; Sechi A; Tartaglia J; Naldi L
Expert Rev Clin Immunol; 2024 Mar; 20(3):255-266. PubMed ID: 37955186
[TBL] [Abstract][Full Text] [Related]
2. Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition.
Simpson EL; Guttman-Yassky E; Eichenfield LF; Boguniewicz M; Bieber T; Schneider S; Guana A; Silverberg JI
Allergy; 2023 Nov; 78(11):2875-2891. PubMed ID: 37455359
[TBL] [Abstract][Full Text] [Related]
3. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
[TBL] [Abstract][Full Text] [Related]
4. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.
Simpson EL; Merola JF; Silverberg JI; Reich K; Warren RB; Staumont-Sallé D; Girolomoni G; Papp K; de Bruin-Weller M; Thyssen JP; Zachariae R; Olsen CK; Wollenberg A
Br J Dermatol; 2022 Dec; 187(6):888-899. PubMed ID: 36082590
[TBL] [Abstract][Full Text] [Related]
5. Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.
Simpson EL; Pink AE; Blauvelt A; Gooderham M; Armstrong AW; Worm M; Katoh N; Peris K; Puig L; Barbarot S; Mark T; Steffensen LA; Tindberg AM; Wollenberg A
Am J Clin Dermatol; 2023 Nov; 24(6):939-952. PubMed ID: 37682422
[TBL] [Abstract][Full Text] [Related]
6. Tralokinumab in Atopic Dermatitis: A Profile of Its Use.
Blair HA
Clin Drug Investig; 2022 Apr; 42(4):365-374. PubMed ID: 35316850
[TBL] [Abstract][Full Text] [Related]
7. The role of tralokinumab in the treatment of atopic dermatitis and future perspectives for adolescents.
Ewulu AR; Prajapati S; Feldman SR
Immunotherapy; 2023 Nov; 15(16):1341-1349. PubMed ID: 37641871
[TBL] [Abstract][Full Text] [Related]
8. Review of Tralokinumab in the Treatment of Atopic Dermatitis.
Singh R; Taylor A; Shah MA; Strowd LC; Feldman SR
Ann Pharmacother; 2023 Mar; 57(3):333-340. PubMed ID: 35730479
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis: A Secondary Analysis.
Merola JF; Butler DC; Mark T; Schneider S; Kim Y; Abuabara K
JAMA Dermatol; 2023 Oct; 159(10):1119-1123. PubMed ID: 37610789
[TBL] [Abstract][Full Text] [Related]
10. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Wollenberg A; Blauvelt A; Guttman-Yassky E; Worm M; Lynde C; Lacour JP; Spelman L; Katoh N; Saeki H; Poulin Y; Lesiak A; Kircik L; Cho SH; Herranz P; Cork MJ; Peris K; Steffensen LA; Bang B; Kuznetsova A; Jensen TN; Østerdal ML; Simpson EL;
Br J Dermatol; 2021 Mar; 184(3):437-449. PubMed ID: 33000465
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial.
Paller AS; Flohr C; Cork M; Bewley A; Blauvelt A; Hong HC; Imafuku S; Schuttelaar MLA; Simpson EL; Soong W; Arlert P; Lophaven KW; Kurbasic A; Soldbro L; Vest NS; Wollenberg A
JAMA Dermatol; 2023 Jun; 159(6):596-605. PubMed ID: 37074705
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis: A phase 2b randomized study.
Silverberg JI; Guttman-Yassky E; Gooderham M; Worm M; Rippon S; O'Quinn S; van der Merwe R; Kragh N; Kurbasic A; Wollenberg A
Ann Allergy Asthma Immunol; 2021 May; 126(5):576-583.e4. PubMed ID: 33333295
[TBL] [Abstract][Full Text] [Related]
13. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial.
Blauvelt A; Langley RG; Lacour JP; Toth D; Laquer V; Beissert S; Wollenberg A; Herranz P; Pink AE; Peris K; Fangel S; Gjerum L; Corriveau J; Saeki H; Warren RB; Simpson E; Reich K
J Am Acad Dermatol; 2022 Oct; 87(4):815-824. PubMed ID: 35863467
[TBL] [Abstract][Full Text] [Related]
14. Tralokinumab for the Treatment of Atopic Dermatitis.
Freitas E; Guttman-Yassky E; Torres T
Am J Clin Dermatol; 2021 Sep; 22(5):625-638. PubMed ID: 34155602
[TBL] [Abstract][Full Text] [Related]
15. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7).
Gutermuth J; Pink AE; Worm M; Soldbro L; Bjerregård Øland C; Weidinger S
Br J Dermatol; 2022 Mar; 186(3):440-452. PubMed ID: 34698371
[TBL] [Abstract][Full Text] [Related]
16. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.
Silverberg JI; Toth D; Bieber T; Alexis AF; Elewski BE; Pink AE; Hijnen D; Jensen TN; Bang B; Olsen CK; Kurbasic A; Weidinger S;
Br J Dermatol; 2021 Mar; 184(3):450-463. PubMed ID: 33000503
[TBL] [Abstract][Full Text] [Related]
17. Tralokinumab in atopic dermatitis.
Wollenberg A; Weidinger S; Worm M; Bieber T
J Dtsch Dermatol Ges; 2021 Oct; 19(10):1435-1442. PubMed ID: 34390128
[TBL] [Abstract][Full Text] [Related]
18. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.
Wollenberg A; Howell MD; Guttman-Yassky E; Silverberg JI; Kell C; Ranade K; Moate R; van der Merwe R
J Allergy Clin Immunol; 2019 Jan; 143(1):135-141. PubMed ID: 29906525
[TBL] [Abstract][Full Text] [Related]
19. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.
Guttman-Yassky E; Kabashima K; Staumont-Salle D; Nahm WK; Pauser S; Da Rosa JC; Martel BC; Madsen DE; Røpke M; Arlert P; Steffensen L; Blauvelt A; Reich K
Allergy; 2024 Jun; 79(6):1560-1572. PubMed ID: 38563683
[TBL] [Abstract][Full Text] [Related]
20. Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis.
Merola JF; Bagel J; Almgren P; Røpke MA; Lophaven KW; Vest NS; Grewal P
J Am Acad Dermatol; 2021 Jul; 85(1):71-78. PubMed ID: 33744356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
